Method Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry for Angiotensin-II in Human Plasma: Application to Study Interaction Between Atorvastatin & Olmesartan Drug Combination
Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was ex...
Saved in:
Published in | Indian journal of clinical biochemistry Vol. 30; no. 3; pp. 334 - 344 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
New Delhi
Springer India
01.07.2015
Springer Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 0970-1915 0974-0422 |
DOI | 10.1007/s12291-014-0457-x |
Cover
Abstract | Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C
18
(cartridges) liquid–liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50–800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity. |
---|---|
AbstractList | Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C18 (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity. Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C 18 (cartridges) liquid–liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50–800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity. Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C.sub.18 (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 x 4.6 mm, 5 [mu]m) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity. Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C 18 (cartridges) liquid–liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50–800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity. Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C18 (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 μm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity. Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C^sub 18^ (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 × 4.6 mm, 5 [mu]m) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATVS + OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS + OLM in combination instead of synergistic activity. |
Audience | Academic |
Author | Pal, Tapan Kumar Das, Rakesh |
Author_xml | – sequence: 1 givenname: Rakesh surname: Das fullname: Das, Rakesh organization: Department of Pharmaceutical Technology, Jadavpur University – sequence: 2 givenname: Tapan Kumar surname: Pal fullname: Pal, Tapan Kumar email: tkpal12@gmail.com organization: Bioequivalence Study Center, Department of Pharmaceutical Technology, Jadavpur University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26089622$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1DAUhSNURH_gAdggS0gIFim24_yxQBqmQEdqVcQUtpbj3GRcJXZqO2XmGXkpPDMtdCpAWTixv3NufO85jPa00RBFzwk-Jhjnbx2htCQxJizGLM3j5aPoAJf5-ovSvc07jklJ0v3o0LkrjBOGGXkS7dMMF2VG6UH08xz8wtToBG6gM0MP2iOha_RddKoWXhmNTIPO1PWoajRdWNMLb1orhsUqvgwg9OhcOIfmA0gfTsHbFWqMRRPdKuNBO6Xj2QwpjU7HXmj0pROuF-_QZBg6JbcVvEFzP9YrNNMerJCbzQ_gfwBoNPHG3gjnA6rRK3TR9eCE9cHqxI4tmpq-Unrj8zR63IjOwbPb9Sj69unj5fQ0Prv4PJtOzmKZYeZjIkidllAVDAhuKCmTVDaszitcZVVasZxKWUGeJlVVQSaTgFUNyzMoiiqnuEyOovdb32Gseqhl6JkVHR-s6oVdcSMU3z3RasFbc8MZy0qc5cHg9a2BNdcjOM975SR0ndBgRsdJwCjJE0oD-vIBemVGq8P1AlUULE0yVvyhWtEBV7oxoa5cm_JJTliYOs3XZY__QoUnTFHJEK1Ghf0dwZsdQWA8LH0rRuf4bP51l31xvym_u3EXtQDkW0Ba45yFhkvlN3MLf6E6TjBfh5pvQ81DqPk61HwZlOSB8s78fxq61bjA6hbsvb79U_QLq3cMdw |
CitedBy_id | crossref_primary_10_1002_bmc_5318 |
Cites_doi | 10.1126/science.173.3991.64 10.1097/00004872-200106001-00004 10.1161/01.HYP.17.2.131 10.1021/ac9707040 10.1056/NEJM199606203342507 10.1161/01.RES.80.2.219 10.1016/0196-9781(91)90070-6 10.1146/annurev.pa.36.040196.001433 10.1016/0003-2697(88)90521-0 10.1016/0378-4347(94)00564-L 10.1056/NEJM197408292910905 10.1146/annurev.physiol.59.1.395 10.1016/S0022-3565(25)19981-3 10.1016/S0031-6997(25)00446-6 |
ContentType | Journal Article |
Copyright | Association of Clinical Biochemists of India 2014 COPYRIGHT 2015 Springer Association of Clinical Biochemists of India 2015 Association of Clinical Biochemists of India 2014 |
Copyright_xml | – notice: Association of Clinical Biochemists of India 2014 – notice: COPYRIGHT 2015 Springer – notice: Association of Clinical Biochemists of India 2015 – notice: Association of Clinical Biochemists of India 2014 |
DBID | AAYXX CITATION NPM ISR 04Q 04W 3V. 7XB 88A 88I 8AO 8FE 8FH 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M2P M7P PHGZM PHGZT PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
DOI | 10.1007/s12291-014-0457-x |
DatabaseName | CrossRef PubMed Gale In Context: Science India Database India Database: Science & Technology ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student SciTech Premium Collection Biological Sciences Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Indian Journals ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Indian Journals: Science & Technology ProQuest One Academic ProQuest Central (Alumni) ProQuest One Academic (New) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 0974-0422 |
EndPage | 344 |
ExternalDocumentID | PMC4469067 3716036861 A714404277 26089622 10_1007_s12291_014_0457_x |
Genre | Journal Article Feature |
GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .VR 04Q 04W 06C 06D 0R~ 0VY 1N0 2.D 203 29I 29~ 2CU 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2WC 2~H 30V 3SX 3V. 4.4 406 408 40D 40E 53G 5GY 5VS 67N 6NX 88A 88I 8AO 8FE 8FH 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABJNI ABJOX ABKCH ABLLD ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACGFS ACGOD ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACSNA ACZOJ ADBBV ADFRT ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFGCZ AFKRA AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG AOIJS ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BAWUL BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BPHCQ C1A CAG CCPQU COF CS3 CSCUP DDRTE DIK DNIVK DPUIP DU5 DWQXO E3Z EBLON EBS EIOEI EJD EN4 ESBYG FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRP FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GX1 H13 HCIFZ HF~ HG6 HH5 HMJXF HRMNR HVGLF HYE HZ~ IAO IEA IHR IJ- IKXTQ INH ISR ITC IWAJR IXC IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV KPH LK8 LLZTM M0L M2P M4Y M7P MA- N2Q NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OK1 P19 PF0 PQQKQ PROAC PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNI ROL RPM RPX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 T16 TR2 TSG TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W2D W48 WK6 WK8 XSB YLTOR Z45 ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ NPM PQGLB AEIIB PMFND 7XB 8FK PKEHL PQEST PQUKI PRINS PUEGO Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c604t-1a1d59eb84e10f21935cf4d7b0b6b5b472ccbe753bbbe6c34e1bf476e88b72093 |
IEDL.DBID | U2A |
ISSN | 0970-1915 |
IngestDate | Thu Aug 21 18:00:48 EDT 2025 Fri Sep 05 07:30:44 EDT 2025 Wed Sep 10 13:41:19 EDT 2025 Tue Jun 17 21:32:13 EDT 2025 Tue Jun 10 20:54:58 EDT 2025 Fri Jun 27 04:46:42 EDT 2025 Mon Jul 21 05:50:40 EDT 2025 Tue Jul 01 05:01:37 EDT 2025 Thu Apr 24 22:58:43 EDT 2025 Fri Feb 21 02:35:11 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Angiotensin-II Atorvastatin Angiotensin-III LCMS/MS Drug interaction Olmesartan |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c604t-1a1d59eb84e10f21935cf4d7b0b6b5b472ccbe753bbbe6c34e1bf476e88b72093 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://link.springer.com/content/pdf/10.1007/s12291-014-0457-x.pdf |
PMID | 26089622 |
PQID | 1688453648 |
PQPubID | 54403 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4469067 proquest_miscellaneous_1690217322 proquest_journals_1688453648 gale_infotracmisc_A714404277 gale_infotracacademiconefile_A714404277 gale_incontextgauss_ISR_A714404277 pubmed_primary_26089622 crossref_citationtrail_10_1007_s12291_014_0457_x crossref_primary_10_1007_s12291_014_0457_x springer_journals_10_1007_s12291_014_0457_x |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-07-01 |
PublicationDateYYYYMMDD | 2015-07-01 |
PublicationDate_xml | – month: 07 year: 2015 text: 2015-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New Delhi |
PublicationPlace_xml | – name: New Delhi – name: India – name: Dordrecht |
PublicationTitle | Indian journal of clinical biochemistry |
PublicationTitleAbbrev | Ind J Clin Biochem |
PublicationTitleAlternate | Indian J Clin Biochem |
PublicationYear | 2015 |
Publisher | Springer India Springer Springer Nature B.V |
Publisher_xml | – name: Springer India – name: Springer – name: Springer Nature B.V |
References | Torchio, Lombardi, Visconti, Doyle (CR13) 1995; 666 Tian, Meng, Chen (CR1) 1974; 291 Kohara, Brosnihan, Chappell (CR17) 1997; 17 Wolny, Clozel, Rein (CR18) 1997; 80 CR4 De Silva, Husain, Smeby, Khairallah (CR16) 1998; 174 Goodfriend, Elliott, Catt (CR7) 1996; 334 McMahon, Kelly (CR15) 1998; 70 Chiu, McCall, Price, Wong, Carini, Duncia (CR11) 1990; 252 Matsukawa, Ichikawa (CR9) 1997; 59 Norwood, Branch, Bridget, Marlon (CR5) 2002; 27 Laeis, Püchler, Kirch (CR6) 2001; 19 Griendling, Lassegue, Alexander (CR8) 1999; 36 Ganong (CR2) 1973 Ardaillou (CR10) 1999; 10 Toshiro, Kei, Terukazu, Yutaka (CR14) 1999; 729 Ganten, Minnich, Granger, Hayduk, Brecht, Barbeau (CR3) 1971; 173 Kohara, Tabuchi, Senanayeke (CR19) 1991; 12 Timmermans, Wong, Chiu, Herblin, Benfield, Carini (CR12) 1993; 45 K Kohara (457_CR19) 1991; 12 R Ardaillou (457_CR10) 1999; 10 WF Ganong (457_CR2) 1973 T Matsukawa (457_CR9) 1997; 59 KK Griendling (457_CR8) 1999; 36 AT Chiu (457_CR11) 1990; 252 GP McMahon (457_CR15) 1998; 70 M Toshiro (457_CR14) 1999; 729 D Norwood (457_CR5) 2002; 27 P Laeis (457_CR6) 2001; 19 A Wolny (457_CR18) 1997; 80 B Tian (457_CR1) 1974; 291 457_CR4 PB Timmermans (457_CR12) 1993; 45 TL Goodfriend (457_CR7) 1996; 334 D Ganten (457_CR3) 1971; 173 L Torchio (457_CR13) 1995; 666 PE Silva De (457_CR16) 1998; 174 K Kohara (457_CR17) 1997; 17 10410930 - J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):89-95 9892138 - J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S30-9 8725391 - Annu Rev Pharmacol Toxicol. 1996;36:281-306 9231832 - Hypertension. 1997 Jul;30(1 Pt 1):128-33 1666184 - Peptides. 1991 Sep-Oct;12(5):1135-41 9074770 - Annu Rev Physiol. 1997;59:395-412 2851278 - Anal Biochem. 1988 Oct;174(1):80-7 9012744 - Circ Res. 1997 Feb;80(2):219-27 7655615 - J Chromatogr B Biomed Appl. 1995 Apr 7;666(1):169-77 8372104 - Pharmacol Rev. 1993 Jun;45(2):205-51 9450367 - Anal Chem. 1998 Jan 15;70(2):409-14 4325865 - Science. 1971 Jul 2;173(3991):64-5 2313596 - J Pharmacol Exp Ther. 1990 Feb;252(2):711-8 11451211 - J Hypertens Suppl. 2001 Jun;19(1):S21-32 8628362 - N Engl J Med. 1996 Jun 20;334(25):1649-54 1846840 - Hypertension. 1991 Feb;17 (2):131-8 |
References_xml | – volume: 173 start-page: 64 issue: 3991 year: 1971 end-page: 65 ident: CR3 article-title: Angiotensin-forming enzyme in brain tissue publication-title: Science doi: 10.1126/science.173.3991.64 – volume: 19 start-page: 21 issue: 1 year: 2001 end-page: 32 ident: CR6 article-title: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction publication-title: J Hypertens Suppl doi: 10.1097/00004872-200106001-00004 – volume: 17 start-page: 131 year: 1997 end-page: 138 ident: CR17 article-title: Angiotensin-(1-7): a member of circulating angiotensin peptides publication-title: Hypertension doi: 10.1161/01.HYP.17.2.131 – volume: 10 start-page: 30 year: 1999 end-page: 39 ident: CR10 article-title: Angiotensin II receptors publication-title: J Am Soc Nephrol – volume: 729 start-page: 89 issue: 2 year: 1999 end-page: 95 ident: CR14 article-title: Determination of angiotensin metabolites in human plasma by fluorimetric high-performance liquid chromatography using a heart-cut column-switching technique publication-title: J Chromatogr B – volume: 70 start-page: 409 issue: 2 year: 1998 end-page: 414 ident: CR15 article-title: Determination of aspirin and salicylic acid in human plasma by column-switching liquid chromatography using on-line solid-phase extraction publication-title: Anal Chem doi: 10.1021/ac9707040 – ident: CR4 – volume: 334 start-page: 1649 year: 1996 end-page: 1654 ident: CR7 article-title: Angiotensin receptors and their antagonists publication-title: N Engl J Med doi: 10.1056/NEJM199606203342507 – volume: 45 start-page: 205 year: 1993 end-page: 251 ident: CR12 article-title: Angiotensin II receptors and angiotensin II receptor antagonists publication-title: Pharmacol Rev – volume: 80 start-page: 219 year: 1997 end-page: 227 ident: CR18 article-title: Functional and biochemical analysis of angiotensin-II forming pathways in human heart publication-title: Circ Res doi: 10.1161/01.RES.80.2.219 – start-page: 342 year: 1973 end-page: 344 ident: CR2 publication-title: Review of medical physiology – volume: 12 start-page: 1135 year: 1991 end-page: 1141 ident: CR19 article-title: Reassessment of plasma angiotensins measurement: effects to protease inhibitors and sample handling procedure publication-title: Peptides doi: 10.1016/0196-9781(91)90070-6 – volume: 36 start-page: 281 year: 1999 end-page: 306 ident: CR8 article-title: Angiotensin receptors and their therapeutic implications publication-title: Annu Rev Pharmacol Toxicol. doi: 10.1146/annurev.pa.36.040196.001433 – volume: 174 start-page: 80 year: 1998 end-page: 87 ident: CR16 article-title: Measurement of Immunoreactive angiotensin peptides in rat tissue: some pitfalls in angiotensin-II analysis publication-title: Anal Biochem doi: 10.1016/0003-2697(88)90521-0 – volume: 27 start-page: 611 issue: 12 year: 2002 end-page: 618 ident: CR5 article-title: Olmesartan medoxomil for hypertension: a clinical review publication-title: Drug Forecast – volume: 666 start-page: 169 issue: 1 year: 1995 end-page: 177 ident: CR13 article-title: Determination of the polar drug dimiracetam in human plasma and serum by column-switching high-performance liquid chromatography publication-title: J Chromatogr B doi: 10.1016/0378-4347(94)00564-L – volume: 252 start-page: 711 year: 1990 end-page: 718 ident: CR11 article-title: Nonpeptide angiotensin-II receptor antagonists, VII: cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent publication-title: J Pharmacol Exp Ther – volume: 291 start-page: 446 year: 1974 end-page: 457 ident: CR1 article-title: Blood Pressures and Cardiovascular Homeostasis in Mice having reduced or absent Angiotensin-Converting Enzyme gene Function publication-title: N Engl J Med doi: 10.1056/NEJM197408292910905 – volume: 59 start-page: 395 year: 1997 end-page: 412 ident: CR9 article-title: Biological functions of angiotensin and its receptors publication-title: Annu Rev Physiol doi: 10.1146/annurev.physiol.59.1.395 – volume: 80 start-page: 219 year: 1997 ident: 457_CR18 publication-title: Circ Res doi: 10.1161/01.RES.80.2.219 – ident: 457_CR4 – volume: 59 start-page: 395 year: 1997 ident: 457_CR9 publication-title: Annu Rev Physiol doi: 10.1146/annurev.physiol.59.1.395 – volume: 36 start-page: 281 year: 1999 ident: 457_CR8 publication-title: Annu Rev Pharmacol Toxicol. doi: 10.1146/annurev.pa.36.040196.001433 – volume: 174 start-page: 80 year: 1998 ident: 457_CR16 publication-title: Anal Biochem doi: 10.1016/0003-2697(88)90521-0 – start-page: 342 volume-title: Review of medical physiology year: 1973 ident: 457_CR2 – volume: 729 start-page: 89 issue: 2 year: 1999 ident: 457_CR14 publication-title: J Chromatogr B – volume: 19 start-page: 21 issue: 1 year: 2001 ident: 457_CR6 publication-title: J Hypertens Suppl doi: 10.1097/00004872-200106001-00004 – volume: 252 start-page: 711 year: 1990 ident: 457_CR11 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)19981-3 – volume: 17 start-page: 131 year: 1997 ident: 457_CR17 publication-title: Hypertension doi: 10.1161/01.HYP.17.2.131 – volume: 334 start-page: 1649 year: 1996 ident: 457_CR7 publication-title: N Engl J Med doi: 10.1056/NEJM199606203342507 – volume: 10 start-page: 30 year: 1999 ident: 457_CR10 publication-title: J Am Soc Nephrol – volume: 27 start-page: 611 issue: 12 year: 2002 ident: 457_CR5 publication-title: Drug Forecast – volume: 173 start-page: 64 issue: 3991 year: 1971 ident: 457_CR3 publication-title: Science doi: 10.1126/science.173.3991.64 – volume: 291 start-page: 446 year: 1974 ident: 457_CR1 publication-title: N Engl J Med doi: 10.1056/NEJM197408292910905 – volume: 666 start-page: 169 issue: 1 year: 1995 ident: 457_CR13 publication-title: J Chromatogr B doi: 10.1016/0378-4347(94)00564-L – volume: 12 start-page: 1135 year: 1991 ident: 457_CR19 publication-title: Peptides doi: 10.1016/0196-9781(91)90070-6 – volume: 45 start-page: 205 year: 1993 ident: 457_CR12 publication-title: Pharmacol Rev doi: 10.1016/S0031-6997(25)00446-6 – volume: 70 start-page: 409 issue: 2 year: 1998 ident: 457_CR15 publication-title: Anal Chem doi: 10.1021/ac9707040 – reference: 9074770 - Annu Rev Physiol. 1997;59:395-412 – reference: 9012744 - Circ Res. 1997 Feb;80(2):219-27 – reference: 8725391 - Annu Rev Pharmacol Toxicol. 1996;36:281-306 – reference: 2313596 - J Pharmacol Exp Ther. 1990 Feb;252(2):711-8 – reference: 9450367 - Anal Chem. 1998 Jan 15;70(2):409-14 – reference: 9231832 - Hypertension. 1997 Jul;30(1 Pt 1):128-33 – reference: 9892138 - J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S30-9 – reference: 7655615 - J Chromatogr B Biomed Appl. 1995 Apr 7;666(1):169-77 – reference: 10410930 - J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):89-95 – reference: 1666184 - Peptides. 1991 Sep-Oct;12(5):1135-41 – reference: 8628362 - N Engl J Med. 1996 Jun 20;334(25):1649-54 – reference: 2851278 - Anal Biochem. 1988 Oct;174(1):80-7 – reference: 4325865 - Science. 1971 Jul 2;173(3991):64-5 – reference: 11451211 - J Hypertens Suppl. 2001 Jun;19(1):S21-32 – reference: 8372104 - Pharmacol Rev. 1993 Jun;45(2):205-51 – reference: 1846840 - Hypertension. 1991 Feb;17 (2):131-8 |
SSID | ssj0034041 |
Score | 2.0041447 |
Snippet | Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human... Simple and sensitive Liquid Chromatography-Tandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human... |
SourceID | pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 334 |
SubjectTerms | Acetonitrile Antihypertensive drugs Antilipemic agents Biochemistry Biomedical and Life Sciences Chemistry/Food Science Chromatography Drug interactions Drug therapy, Combination Formic acid Hypertension Life Sciences Liquid chromatography Mass spectrometry Methods Microbiology Organic acids Original Original Article Pathology Plasma Statins Studies |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAviG8KAx0IgQSKyIftJLygDjatiI5pbGhvke04oxJLtjZF29_IP8Vd4rRNJfbsixPH5_N9_O6OsddBKkJluPWEIdeN0XjmQmWpa6ohkIIwmpKTx_ty75h_PREnzuE2c7DKTiY2gjqvDPnIPwQySbiIJE8-nV941DWKoquuhcZNtokiOEE-39ze2T847GRxxP2md6Wfxr6Hlono4ppN8lwYEuonICCGiL3L3s20Lp9XLqh18ORaBLW5mHbvsjtOo4RhywL32A1b3me3xi5m_oD9HTdNomEFHgSqzOEnauBtQyWoCvg2uZhPcqBauajDujrW3hG5mM9gjBo2UKf6moob1NMrQFUXhuXppGoA8KU3GsGkhCYiAAeokJ-pjzBcxsahroAQi1fQeCDbZArYbjFiMES7_4-i1Cac4w18pyQJ5Gic6st0fgoostB8b-Z5yI53d44-73muhYNnpM9rL1BBLlKrE24Dv0DpGAlT8DzWvpZaaB6HxmiLJpPW2koTIZkueCxtkug49NPoEdsoq9I-YSDDQkUaRYwVKaoVQgVFnibGz2Vq0kCrAfO77cuMq29ObTZ-Z8vKzLTjGe54RjueXQ7Yu8Uj521xj-uIXxFPZFQ0oyRUzqmaz2bZ6MdhNowpRM7DOB6wt46oqPDlRrkkB1wC1dnqUW71KPFUm_5wx3qZkyqzbHkGBuzlYpieJKRcaas50aRkZqKcHrDHLacu1oa2a5JKGol7PLwgoFrj_ZFy8qupOc7JjSLxs9533L7yWf_7ZU-vX8QzdhvVT9GCn7fYRj2d2-eo4tX6hTvH_wAqnFJ_ priority: 102 providerName: ProQuest |
Title | Method Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry for Angiotensin-II in Human Plasma: Application to Study Interaction Between Atorvastatin & Olmesartan Drug Combination |
URI | https://link.springer.com/article/10.1007/s12291-014-0457-x https://www.ncbi.nlm.nih.gov/pubmed/26089622 https://www.proquest.com/docview/1688453648 https://www.proquest.com/docview/1690217322 https://pubmed.ncbi.nlm.nih.gov/PMC4469067 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9NAEF6hVkK8IG4MJRoQAglkyceuD95cSGmAlKo0qH2ydtfrEInakDiI_kb-FDM-kjgCJJ78sOP1sbOzc3wzw9hTNxae1NzYQpPrRivcc5401DVVE0hBaEXJyeOj4HDC352JszaPe9Gh3buQZC2p18lunkcoHZeAEyK0UXHcFWi6026ceEknfn3u1O0qnTh0bDRGRBfK_NMUvcNoWyRvnEnbeMmtoGl9Fh3cYNdbJRKSZtVvsiumuMWujtsw-W32a1z3hYYNRBDIIoPPqHQ3PZSgzOHD7PtylgGVx0W1tS1dbZ-SV_kCxqhUAzWnr6ieQTW_BNRuISmms7LGvBf2aASzAuogAByjDn4hX0GyDodDVQKBFC-hdjo2-ROw38DCIEFT_4ekbCac4xl8pLwIZGKc6s18OQWUUmix1_PcYZOD4enrQ7vt2mDrwOGV7Uo3E7FRETeuk6NA9IXOeRYqRwVKKB56WiuDVpJSygTaRzKV8zAwUaRCz4n9u2ynKAtzn0Hg5dJXKFWMiFGTENLNszjSThbEOnaVtJjTLV-q25Lm1Fnja7ouxkwrnuKKp7Ti6U-LvVjd8q2p5_Ev4ifEEynVySgIiDOVy8UiHX06SZOQouLcC0OLPW-J8hIfrmWb14CfQKW1epR7PUrcyLo_3LFe2gqSReoGUcSFH_DIYo9Xw3QngeMKUy6JJibLEkWzxe41nLr6NjRXozigkbDHwysCKi_eHylmX-oy45w8JwG-1suO2zde62-_7MF_UT9k11ABFQ38eY_tVPOleYRKXqUGbDd5e_5-iNf94dHxyaD2ww3qrf4boS1SRg |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF5VqQS8IG4CBQbEIYEsbGfXBxJCKW2V0CRUbYr6ZrzrdbBE7DQHNH-KP8KfYsZHLom-9XnHjjdz7OzMNzOMvbR8YYeKa0MoCt0oiTpnh5qmpioCKQglqTi523Nap_zLmTjbYn-qWhiCVVY2MTfUUaYoRv7ecjyPi4bDvU-jc4OmRlF2tRqhUYjFoZ7_xivb5GN7D_n7yrYP9vufW0Y5VcBQjsmnhhVakfC19Li2zBgVtiFUzCNXmtKRQnLXVkpq9OKllNpRDSSTMXcd7XnStfPmS2jytzlVtNbY9u5-7-i4sv0NbuazMk3fNQ28CYkqj5oX69k2oYwsAn4I17hYOwk3z4OVA3ETrLmRsc0PwoNb7GbpwUKzELnbbEund9i1bpmjv8v-dvOh1LACR4IwjeAbevzFACfIYugk57MkAurNiz5z2Tfb6FNIewhd9OjhZJQP6Bnq6XgO6FpDMx0kWQ64T412G5IU8gwEHOEFYBh-gOYyFw_TDAghOYc84lkUb8BugUmD5jQb_wqplArf8Rq-UlEGahC-am88GwCaSJkUQdJ77PRKmHuf1dIs1Q8ZOHYcNiSaNC18dGNEaMWR7ykzcnzlWzKsM7NiX6DKfuo01uNnsOwETRwPkOMBcTy4qLO3i0dGRTORy4hfkEwE1KQjJRTQIJxNJkH75DhoupSS57br1tmbkijO8MdVWBZV4Baor9ca5c4aJVoRtb5ciV5QWrFJsNS5Onu-WKYnCZmX6mxGND5da_FcqLMHhaQu9oZ3Zc93aMVdk-EFAfU2X19Jkx95j3NOYRsHP-tdJe0rn_W_v-zR5Zt4xq63-t1O0Gn3Dh-zG-j6igJ4vcNq0_FMP0H3ciqfljoN7PtVm5F_mxeQQg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELbQkCa-IN7pGHAgBBIoWl5sJ-FbYFQrrGOCDe1bZDtOqcSS0aaI_Ub-FHd5aZsKkPjsi5vU5_Od77nnGHvmxcJXhltHGLq6MRr3nK8sdU01BFIQRlNx8vhIHpzy92firO1zOu_Q7l1KsqlpIJamotq7yPK9VeGb7xNixyMQhQgddCKvojX2SNFP_aQzxQF369aVbhy6DgYmoktr_mmK3sG0aZ7XzqdN7ORGArU-l4Y32PXWoYSk0YCb7IotbrHtcZsyv81-jese0bCGDgJVZPAFHfCmnxKUORxOvy-mGRBVLrqwLY21c0I3zOcwRgcbqFF9RdwG1ewS0NOFpJhMyxr_XjijEUwLqBMCcIz--Ll6DckqNQ5VCQRYvIT6ArKppYA3DUQMEgz7fyiqbMI5nsNHqpFAhcap9meLCaDFwui9nucOOx2-O3l74LQdHBwjXV45nvIyEVsdceu5ORrHQJicZ6F2tdRC89A3RluMmLTWVpoAxXTOQ2mjSIe-Gwd32VZRFvY-A-nnKtBoYayI0asQysuzODJuJmMTe1oNmNstX2paenPqsvEtXREz04qnuOIprXj6c8BeLh-5aLg9_iX8lHQiJc6MgkA5E7WYz9PR509pElKGnPthOGAvWqG8xB83qq1xwE8gmq2e5G5PEje16Q93qpe2RmWeejKKuAgkjwbsyXKYniSgXGHLBcnEFGWimR6we42mLr8NQ9coljQS9nR4KUBU4_2RYvq1phzndIsi8bVeddq-9lp_-8t2_kv6Mds-3h-mh6OjDw_YNfRLRYOK3mVb1WxhH6LvV-lH9f7-DQlRVTc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Method+Development+and+Validation+of+Liquid+Chromatography-Tandem+Mass+Spectrometry+for+Angiotensin-II+in+Human+Plasma%3A+Application+to+Study+Interaction+Between+Atorvastatin+%26+Olmesartan+Drug+Combination&rft.jtitle=Indian+journal+of+clinical+biochemistry&rft.au=Das%2C+Rakesh&rft.au=Pal%2C+Tapan+Kumar&rft.date=2015-07-01&rft.issn=0970-1915&rft.eissn=0974-0422&rft.volume=30&rft.issue=3&rft.spage=334&rft.epage=344&rft_id=info:doi/10.1007%2Fs12291-014-0457-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12291_014_0457_x |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0970-1915&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0970-1915&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0970-1915&client=summon |